SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 29, 2021
(Exact name of registrant as specified in its charter)
|(State or other jurisdiction of||(Commission||(I.R.S. Employer|
|incorporation)||File Number)||Identification No.)|
3800 Bridge Parkway, Suite 102
Redwood City, California 94065
(Address of principal executive offices, including zip code)
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last reports)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|☐||Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)|
|☐||Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)|
|☐||Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))|
|☐||Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))|
|Title of each class||Trading Symbol||Name of each exchange on which registered|
|Class A Common Stock, par value $0.00001 per share||SEER|
The NASDAQ Stock Market LLC
(The NASDAQ Global Select Market)
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
The board of directors (the “Board”) of Seer, Inc. (the “Company”) increased the authorized size of the Board from nine directors to ten directors effective November 29, 2021. Contemporaneously, Meeta Gulyani was appointed to the Board. Ms. Gulyani will serve as a Class III director, with a term expiring at the Company’s 2023 annual meeting of the stockholders.
In accordance with the Company’s outside director compensation policy (the “policy”), Ms. Gulyani will receive annual cash compensation of $40,000 for her services as a member of the Board and annual cash compensation in accordance with the policy for her service on those committees of the Board on which she serves, if any. In addition, in accordance with the policy, on November 29, 2021, Ms. Gulyani was automatically granted an initial award of a stock option to purchase 30,000 shares of the Company’s common stock (the “Initial Award”). The Initial Award is scheduled to vest as to one thirty-sixth (1/36th) of the shares subject to the Initial Award on a monthly basis following the Initial Award’s grant date on the same day of the month as the grant date of the Initial Award (or on the last day of the month, if there is no corresponding day in such month), provided that she remains a service provider through the applicable vesting date. The initial award to Ms. Gulyani was granted under and subject to terms of the Company’s 2020 Equity Incentive Plan.
Ms. Gulyani will be eligible for equity awards on the same terms as other continuing non-employee members of the Board. Currently, the policy provides that, subject to the compensation limits of the policy, on the first trading day immediately following the date of each annual meeting of stockholders, each non-employee director automatically will be granted an award of stock options to purchase 15,000 shares of the Company’s common stock (the “Annual Award”); provided, however, that if an individual commenced service as a non-employee director after the date of the annual meeting of stockholders that occurred immediately prior to such annual meeting, then the Annual Award granted to such non-employee director will be prorated based on the number of whole months that the individual served as a non-employee director prior to the Annual Award’s grant date during the twelve (12) month period immediately preceding such annual meeting (with any resulting fractional share rounded down to the nearest whole share). The Annual Award will be scheduled to vest as to all of the shares subject to the Annual Award on the earlier of (i) the one (1) year anniversary of the date the Annual Award is granted or (ii) the day immediately before the date of the next annual meeting of stockholders that occurs after the Annual Award’s grant date, provided that such director remains a service provider through the applicable vesting date.
The policy provides that each equity award granted to a non-employee director while a non-employee director will vest in full as of immediately prior to a change in control, provided they continue to be a non-employee director through the date of such change in control.
Ms. Gulyani also executed the Company’s standard form of indemnification agreement, a copy of which has been filed as Exhibit 10.1 to the Company’s Registration Statement on Form S-1 (File No. 333-250035) filed with the Securities and Exchange Commission on November 12, 2020.
There is no arrangement or understanding between Ms. Gulyani and any other persons pursuant to which Ms. Gulyani was elected as a director. In addition, Ms. Gulyani is not a party to any transaction, or series of transactions, required to be disclosed pursuant to Item 404(a) of Regulation S-K.
On November 29, 2021, the Company issued a press release announcing the appointment of Ms. Gulyani as a director. The press release is attached hereto as Exhibit 99.1.
Item 9.01 Financial Statements and Exhibits.
|Press Release dated November 29, 2021|
|104||Cover Page Interactive Data File (formatted as Inline XBRL)|
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|Date:||November 29, 2021||By:||/s/ David Horn|
|Chief Financial Officer|
Seer Appoints Meeta Gulyani to its Board of Directors
Redwood City, Calif., Nov. 29, 2021 — Seer, Inc., (Nasdaq: SEER), a life sciences company commercializing a disruptive new platform for proteomics, today announced it has appointed Meeta Gulyani to serve on its Board of Directors. Ms. Gulyani is currently Executive Vice President, Head of Strategy, Business Development and Transformation for the Life Science business of Merck KGaA, Darmstadt, Germany, a global science and technology company, which operates as MilliporeSigma in the U.S. and Canada.
“Meeta is a seasoned life sciences and pharma leader with global experience across markets, including Asia, an important market for Seer, and we are really pleased to welcome Meeta to our Board,” said Omid Farokhzad, M.D., Chair, Chief Executive Officer and Founder of Seer. “Meeta’s experience, expertise and passion for innovation in healthcare will be an asset to the Seer Board and accelerating our mission of opening up a new gateway to the proteome.”
“I am honored to join the Seer Board and excited to contribute to the company’s mission,” said Ms. Gulyani. “Seer is redefining what’s possible in proteomics, creating a path to drive new insights and revolutionize our understanding of biology – it truly is the next frontier in human health. I look forward to partnering with the Seer team to accelerate this incredible transformation."
|In her current role as Head of Strategy, Business Development and Transformation for the Life Science business of Merck KGaA, Darmstadt, Germany, Meeta leads the development of the Life Science sector strategy and searches out and delivers deals of value to enable the achievement of its growth ambition. Meeta was previously Executive Vice President and Head of Strategy and Global Franchises for the Biopharma business of Merck KGaA, Darmstadt, Germany. Prior to that, she served as General Manager for Roche South Asia, and Vice President, Head of Global Portfolio Management at Roche. Prior to Roche, Meeta held several marketing and sales leadership positions within Sanofi. She also served as a strategy consultant with the Monitor Consulting Group based in Hong Kong and the United States. Meeta holds a M.B.A. from the Asian Institute of Management, Philippines, accompanied by an exchange program at the Wharton School of the University of |
|Pennsylvania. She earned a bachelor’s degree in economics from the Shri Ram College of Commerce at Delhi University in India. |
About Seer Inc.
Seer™ is a life sciences company developing transformative products that open a new gateway to the proteome. Seer is commercializing its Proteograph™ Product Suite, an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours. Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures. For more information, please visit www.seer.bio.